Article: Data Suggest SEROQUEL is More Effective than Haloperidol in Patients with Treatment-Resistant Schizophrenia.

NEW ORLEANS, May 8 /PRNewswire/ --

Data being presented today at the American Psychiatric Association annual meeting suggest that the atypical antipsychotic SEROQUEL(R) (quetiapine fumarate) Tablets, a product of AstraZeneca (NYSE: AZN), is more effective than haloperidol in treating patients with schizophrenia resistant to fluphenazine, a conventional antipsychotic medication. Compared with haloperidol, SEROQUEL patients experienced fewer extrapyramidal symptoms (EPS) -- a common debilitating side effect of conventional antipsychotics -- and decreased prolactin levels(1). SEROQUEL Tablets are indicated for the treatment of schizophrenia.

"Schizophrenia ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!